Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-08-03
Completion Date
2027-08-03
Last Updated
2022-08-10
Healthy Volunteers
No
Conditions
Interventions
Vγ2Vδ2 T lymphocyte-based immunotherapy
Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
Treatment regimens for MDR-TB
Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Locations (2)
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China